Highmark BCBS to Cover MDxHealth Prostate Cancer Test
News Oct 07, 2016
MDxHealth SA has announced that the Highmark BCBS (Highmark) has issued a positive medical coverage policy decision for the ConfirmMDx® for Prostate Cancer test. This positive coverage policy is in line with the positive medical policy recently implemented by Independence Blue Cross and represents the second Blue Cross Blue Shield Association (BCBSA) licensee to establish coverage for commercial and Medicare members for ConfirmMDx.
Highmark is a national, diversified health care partner based in Pittsburgh that serves members across the United States through businesses in health insurance, dental insurance, vision care and reinsurance. Highmark, and its affiliates, operate health insurance plans in Pennsylvania, Delaware and West Virginia that serve 5.2 million members. Highmark is among the largest health insurers in the United States and is the fourth largest Blue Cross and Blue Shield-affiliated company.
"Highmark Blue Cross Blue Shield's positive policy decision adds to the momentum we are seeing in payer adoption of the ConfirmMDx for Prostate Cancer test," stated Dr. Jan Groen, CEO of MDxHealth. "This decision further validates the impact ConfirmMDx has on patient outcomes and reduction in cost to the US healthcare system."
Targeting Epigenetic Proteins to Prevent Breast CancerNews
Researchers have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone. The study suggests that inhibiting these proteins with drugs could prevent the development of breast cancer in women at high risk of the disease.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Targeting the Engine Room of the Cancer CellNews
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug combinations that are most likely to kill them.READ MORE